151. Experimental Induction of Bacterial Resistance to the Antimicrobial Peptide Tachyplesin I and Investigation of the Resistance Mechanisms.
- Author
-
Hong J, Hu J, and Ke F
- Subjects
- Aeromonas hydrophila genetics, Aeromonas hydrophila radiation effects, Aeromonas hydrophila ultrastructure, Amikacin pharmacology, Cefoperazone pharmacology, Dose-Response Relationship, Drug, Drug Resistance, Bacterial genetics, Drug Resistance, Bacterial radiation effects, Escherichia coli genetics, Escherichia coli radiation effects, Escherichia coli ultrastructure, Microbial Sensitivity Tests, Mutation, Proteolysis, Pseudomonas aeruginosa genetics, Pseudomonas aeruginosa radiation effects, Pseudomonas aeruginosa ultrastructure, Selection, Genetic, Ultraviolet Rays, Aeromonas hydrophila drug effects, Anti-Bacterial Agents pharmacology, Antimicrobial Cationic Peptides pharmacology, DNA-Binding Proteins pharmacology, Drug Resistance, Bacterial drug effects, Escherichia coli drug effects, Peptides, Cyclic pharmacology, Pseudomonas aeruginosa drug effects
- Abstract
Tachyplesin I is a 17-amino-acid cationic antimicrobial peptide (AMP) with a typical cyclic antiparallel β-sheet structure that is a promising therapeutic for infections, tumors, and viruses. To date, no bacterial resistance to tachyplesin I has been reported. To explore the safety of tachyplesin I as an antibacterial drug for wide clinical application, we experimentally induced bacterial resistance to tachyplesin I by using two selection procedures and studied the preliminary resistance mechanisms. Aeromonas hydrophila XS91-4-1, Pseudomonas aeruginosa CGMCC1.2620, and Escherichia coli ATCC 25922 and F41 showed resistance to tachyplesin I under long-term selection pressure with continuously increasing concentrations of tachyplesin I. In addition, P. aeruginosa and E. coli exhibited resistance to tachyplesin I under UV mutagenesis selection conditions. Cell growth and colony morphology were slightly different between control strains and strains with induced resistance. Cross-resistance to tachyplesin I and antimicrobial agents (cefoperazone and amikacin) or other AMPs (pexiganan, tachyplesin III, and polyphemusin I) was observed in some resistant mutants. Previous studies showed that extracellular protease-mediated degradation of AMPs induced bacterial resistance to AMPs. Our results indicated that the resistance mechanism of P. aeruginosa was not entirely dependent on extracellular proteolytic degradation of tachyplesin I; however, tachyplesin I could induce increased proteolytic activity in P. aeruginosa Most importantly, our findings raise serious concerns about the long-term risks associated with the development and clinical use of tachyplesin I., (Copyright © 2016, American Society for Microbiology. All Rights Reserved.)
- Published
- 2016
- Full Text
- View/download PDF